Perimeter Medical Imaging AI Graduates to Tier 1 of the TSX-V
03 Octubre 2022 - 6:45AM
Business Wire
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF)
(FSE:4PC) (“Perimeter” or the “Company”) – a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs – announces that the TSX Venture Exchange
(TSX-V) has approved its application to graduate from a Tier 2
Issuer to a Tier 1 Issuer. Tier 1 is reserved for senior TSX-V
companies with the most significant financial resources and those
that have demonstrated a sustainable business model and operational
track record.
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “We
are very pleased that the TSX-V has recognized Perimeter’s growth
since it became public in 2020. We were already recognized as part
of the 2022 TSX Venture 50®, and to us this graduation is the
natural next step. We look forward to continuing to grow our
business and providing value to our shareholders as a Tier 1
company.”
Important factors included in Perimeter’s successful tier
graduation application include the Company’s well capitalized
position with cash and cash equivalents of $44,966,273 as of June
30, 2022; Perimeter’s significant intellectual property in its
optical tissue imaging system including five issued patents in the
U.S. and internationally; and the broadening public distribution of
Perimeter’s common shares traded on the TSX-V, OTC and FSE.
Perimeter’s common shares will begin trading on Tier 1 at the
open of trading on October 5, 2022.
With the graduation to Tier 1 listing, Perimeter’s common shares
previously deposited into escrow pursuant to TSX-V rules will now
be governed by the applicable Tier 1 release provisions. As such,
5,080,959 common shares of Perimeter as well as
approximately 687,105 warrants, options or underlying common shares
of Perimeter will be eligible for release from escrow immediately,
including 5,008,057 common shares held by Perimeter’s largest
shareholder, Roadmap Capital.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the Cancer Prevention and Research
Institute of Texas. The company’s ticker symbol “PINK” is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the development and potential
benefits of Perimeter S-Series OCT, Perimeter B-Series OCT and
Perimeter ImgAssist are forward-looking information.
Forward-looking statements should not be read as guarantees of
future performance or results, and will not necessarily be accurate
indications of whether, or the times at or by which, any particular
result will be achieved. No assurance can be given that any events
anticipated by the forward-looking information will transpire or
occur. Forward-looking information is based on information
available at the time and/or management’s good-faith belief with
respect to future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2021, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
Perimeter does not intend, nor does Perimeter undertake any
obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003005378/en/
Chris Scott Chief Financial Officer Perimeter Medical Imaging
AI, Inc. Investors: investors@perimetermed.com Toll-free:
888-988-7465 (PINK)
Jodi Regts Corporate Communications Perimeter Medical Imaging
AI, Inc. Media: media@perimetermed.com Mobile: 469-743-1834
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025